{"transactions":[{"id":687419,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-14T20:05:31.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":7000,"derivative":{"exercise_price":13.05,"expiration_date":"2028-05-02","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001140361-26-033143","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126033143/form4.xml","form_type":"4"}},{"id":687418,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-08-14T20:05:31.000Z","date":"2026-08-12","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":44.53,"value":311710.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025."}],"balance_after":18300,"source":{"system":"sec-edgar","filing":"0001140361-26-033143","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126033143/form4.xml","form_type":"4"}},{"id":687417,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-08-14T20:05:31.000Z","date":"2026-08-12","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":13.05,"value":91350.0,"ownership":{"direct":true},"balance_after":25300,"source":{"system":"sec-edgar","filing":"0001140361-26-033143","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126033143/form4.xml","form_type":"4"}},{"id":767648,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-21T20:49:01.000Z","date":"2026-05-19","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 19, 2026 and vests in full upon the earlier of (i) May 19, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":1.04,"expiration_date":"2036-05-18","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001193125-26-234665","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000119312526234665/ownership.xml","form_type":"4"}},{"id":777889,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-15T20:06:59.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 2, 2018, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":14000,"derivative":{"exercise_price":13.05,"expiration_date":"2028-05-02","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001140361-26-021656","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/form4.xml","form_type":"4"}},{"id":777888,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-15T20:06:59.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":0,"derivative":{"exercise_price":2.63,"expiration_date":"2027-05-03","underlying":"Common Stock","underlying_shares":3500},"source":{"system":"sec-edgar","filing":"0001140361-26-021656","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/form4.xml","form_type":"4"}},{"id":777887,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-15T20:06:59.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":3500,"price":32.82,"value":114870.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025."}],"balance_after":18300,"source":{"system":"sec-edgar","filing":"0001140361-26-021656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/form4.xml","form_type":"4"}},{"id":777886,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-15T20:06:59.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":true,"shares":3500,"price":13.05,"value":45675.0,"ownership":{"direct":true},"balance_after":21800,"source":{"system":"sec-edgar","filing":"0001140361-26-021656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/form4.xml","form_type":"4"}},{"id":777885,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-15T20:06:59.000Z","date":"2026-05-13","kind":"sale","planned":true,"acquired":false,"shares":3500,"price":32.83,"value":114905.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 12, 2025."}],"balance_after":18300,"source":{"system":"sec-edgar","filing":"0001140361-26-021656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/form4.xml","form_type":"4"}},{"id":777884,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-15T20:06:59.000Z","date":"2026-05-13","kind":"exercise","planned":true,"acquired":true,"shares":3500,"price":2.63,"value":9205.0,"ownership":{"direct":true},"balance_after":21800,"source":{"system":"sec-edgar","filing":"0001140361-26-021656","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126021656/form4.xml","form_type":"4"}},{"id":796222,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-05-01T20:06:06.000Z","date":"2026-04-29","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs vest 100% on the earlier of April 29, 2027, or the date of the first Annual Meeting of Stockholders following April 29, 2026."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":3200,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-26-018544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126018544/form4.xml","form_type":"4"}},{"id":796221,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-05-01T20:06:06.000Z","date":"2026-04-29","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company."}],"balance_after":8000,"derivative":{"exercise_price":33.43,"expiration_date":"2036-04-29","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001140361-26-018544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126018544/form4.xml","form_type":"4"}},{"id":796220,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2026-05-01T20:06:06.000Z","date":"2026-04-29","kind":"exercise","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-26-018544","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126018544/form4.xml","form_type":"4"}},{"id":796219,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-05-01T20:06:06.000Z","date":"2026-04-29","kind":"exercise","planned":false,"acquired":true,"shares":3200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 30, 2025."}],"balance_after":18300,"source":{"system":"sec-edgar","filing":"0001140361-26-018544","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126018544/form4.xml","form_type":"4"}},{"id":906180,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2026-02-13T21:05:48.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":3500,"derivative":{"exercise_price":2.63,"expiration_date":"2027-05-03","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001140361-26-005417","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126005417/form4.xml","form_type":"4"}},{"id":906179,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-13T21:05:48.000Z","date":"2026-02-11","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":34.66,"value":242620.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":15100,"source":{"system":"sec-edgar","filing":"0001140361-26-005417","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126005417/form4.xml","form_type":"4"}},{"id":906178,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2026-02-13T21:05:48.000Z","date":"2026-02-11","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":2.63,"value":18410.0,"ownership":{"direct":true},"balance_after":22100,"source":{"system":"sec-edgar","filing":"0001140361-26-005417","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036126005417/form4.xml","form_type":"4"}},{"id":992372,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2025-11-20T21:22:07.000Z","date":"2025-11-19","kind":"purchase","planned":false,"acquired":true,"shares":50000,"price":2.5,"value":125000.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares of common stock acquired in an underwritten public offering."}],"balance_after":50000,"source":{"system":"sec-edgar","filing":"0001193125-25-289825","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000119312525289825/ownership.xml","form_type":"4"}},{"id":1002964,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-12T21:06:00.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase a total of 17,500 shares, were originally granted on May 3, 2017, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":10500,"derivative":{"exercise_price":2.63,"expiration_date":"2027-05-03","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001140361-25-041647","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125041647/form4.xml","form_type":"4"}},{"id":1002963,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-11-12T21:06:00.000Z","date":"2025-11-10","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":38.59,"value":270130.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":15100,"source":{"system":"sec-edgar","filing":"0001140361-25-041647","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125041647/form4.xml","form_type":"4"}},{"id":1002962,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-11-12T21:06:00.000Z","date":"2025-11-10","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":2.63,"value":18410.0,"ownership":{"direct":true},"balance_after":22100,"source":{"system":"sec-edgar","filing":"0001140361-25-041647","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125041647/form4.xml","form_type":"4"}},{"id":1071786,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-08-08T20:05:27.000Z","date":"2025-08-06","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":0,"derivative":{"exercise_price":2.76,"expiration_date":"2026-05-04","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001140361-25-029856","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125029856/form4.xml","form_type":"4"}},{"id":1071785,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-08-08T20:05:27.000Z","date":"2025-08-06","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":35.92,"value":251440.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":15100,"source":{"system":"sec-edgar","filing":"0001140361-25-029856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125029856/form4.xml","form_type":"4"}},{"id":1071784,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-08-08T20:05:27.000Z","date":"2025-08-06","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":2.76,"value":19320.0,"ownership":{"direct":true},"balance_after":22100,"source":{"system":"sec-edgar","filing":"0001140361-25-029856","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125029856/form4.xml","form_type":"4"}},{"id":1136838,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-22T20:14:02.000Z","date":"2025-05-20","kind":"grant","planned":false,"acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 20, 2025 and vests in full upon the earlier of (i) May 20, 2026 or (ii) the date of the Issuer's 2026 Annual Meeting of Stockholders, subject to the Reporting Person's continuous service through such vesting date."}],"balance_after":50000,"derivative":{"exercise_price":0.8092,"expiration_date":"2035-05-19","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0000950170-25-076332","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000095017025076332/ownership.xml","form_type":"4"}},{"id":1154429,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-09T20:05:21.000Z","date":"2025-05-07","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":7000,"derivative":{"exercise_price":2.76,"expiration_date":"2026-05-04","underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001140361-25-018156","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125018156/form4.xml","form_type":"4"}},{"id":1154428,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-09T20:05:21.000Z","date":"2025-05-07","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":39.98,"value":279860.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":15100,"source":{"system":"sec-edgar","filing":"0001140361-25-018156","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125018156/form4.xml","form_type":"4"}},{"id":1154427,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-09T20:05:21.000Z","date":"2025-05-07","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":2.76,"value":19320.0,"ownership":{"direct":true},"balance_after":22100,"source":{"system":"sec-edgar","filing":"0001140361-25-018156","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125018156/form4.xml","form_type":"4"}},{"id":1161774,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2025-05-02T20:07:01.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs vest 100% on the earlier of April 30, 2026, or the date of the first Annual Meeting of Stockholders following April 30, 2025."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":3200,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-25-017117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125017117/form4.xml","form_type":"4"}},{"id":1161773,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-05-02T20:07:01.000Z","date":"2025-04-30","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company."}],"balance_after":8000,"derivative":{"exercise_price":38.02,"expiration_date":"2035-04-30","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001140361-25-017117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125017117/form4.xml","form_type":"4"}},{"id":1161772,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2025-05-02T20:07:01.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-25-017117","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125017117/form4.xml","form_type":"4"}},{"id":1161771,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-05-02T20:07:01.000Z","date":"2025-04-30","kind":"exercise","planned":false,"acquired":true,"shares":3200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 1, 2024."}],"balance_after":15100,"source":{"system":"sec-edgar","filing":"0001140361-25-017117","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125017117/form4.xml","form_type":"4"}},{"id":1268448,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T21:05:37.000Z","date":"2025-02-12","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options, representing the right to purchase a total of 15,000 shares, were originally granted on May 4, 2016, and became exercisable in equal monthly installments over the course of one year, contingent upon continued service to the Company."}],"balance_after":14000,"derivative":{"exercise_price":2.76,"expiration_date":"2026-05-04","underlying":"Common Stock","underlying_shares":1000},"source":{"system":"sec-edgar","filing":"0001140361-25-004765","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125004765/form4.xml","form_type":"4"}},{"id":1268447,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2025-02-14T21:05:37.000Z","date":"2025-02-12","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025"}],"balance_after":0,"derivative":{"exercise_price":3.74,"underlying":"Common Stock","underlying_shares":6000},"source":{"system":"sec-edgar","filing":"0001140361-25-004765","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125004765/form4.xml","form_type":"4"}},{"id":1268446,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-14T21:05:37.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":1000,"price":55.43,"value":55430.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":11900,"source":{"system":"sec-edgar","filing":"0001140361-25-004765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125004765/form4.xml","form_type":"4"}},{"id":1268445,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-14T21:05:37.000Z","date":"2025-02-12","kind":"exercise","planned":true,"acquired":true,"shares":1000,"price":2.76,"value":2760.0,"ownership":{"direct":true},"balance_after":12900,"source":{"system":"sec-edgar","filing":"0001140361-25-004765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125004765/form4.xml","form_type":"4"}},{"id":1268444,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-14T21:05:37.000Z","date":"2025-02-12","kind":"sale","planned":true,"acquired":false,"shares":6000,"price":55.47,"value":332820.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":11900,"source":{"system":"sec-edgar","filing":"0001140361-25-004765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125004765/form4.xml","form_type":"4"}},{"id":1268443,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2025-02-14T21:05:37.000Z","date":"2025-02-12","kind":"exercise","planned":true,"acquired":true,"shares":6000,"price":3.74,"value":22440.0,"ownership":{"direct":true},"balance_after":17900,"source":{"system":"sec-edgar","filing":"0001140361-25-004765","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036125004765/form4.xml","form_type":"4"}},{"id":1364375,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-11-15T21:05:21.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025."}],"balance_after":6000,"derivative":{"exercise_price":3.74,"underlying":"Common Stock","underlying_shares":7000},"source":{"system":"sec-edgar","filing":"0001140361-24-047070","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124047070/form4.xml","form_type":"4"}},{"id":1364374,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-11-15T21:05:21.000Z","date":"2024-11-13","kind":"sale","planned":true,"acquired":false,"shares":7000,"price":55.54,"value":388780.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":11900,"source":{"system":"sec-edgar","filing":"0001140361-24-047070","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124047070/form4.xml","form_type":"4"}},{"id":1364373,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-11-15T21:05:21.000Z","date":"2024-11-13","kind":"exercise","planned":true,"acquired":true,"shares":7000,"price":3.74,"value":26180.0,"ownership":{"direct":true},"balance_after":18900,"source":{"system":"sec-edgar","filing":"0001140361-24-047070","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124047070/form4.xml","form_type":"4"}},{"id":1437425,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:05:22.000Z","date":"2024-08-07","kind":"grant","planned":true,"acquired":true,"shares":2000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"These options, representing the right to purchase 15,000 shares, were originally granted on March 20, 2015, with 624 shares becoming exercisable on the grant date, 312 shares becoming exercisable on March 31, 2015, and the remainder becoming exercisable in equal monthly installments, contingent upon continued service to the Company, from April 30, 2015 through December 31, 2017."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025."}],"balance_after":13000,"derivative":{"exercise_price":3.74,"underlying":"Common Stock","underlying_shares":2000},"source":{"system":"sec-edgar","filing":"0001140361-24-036617","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124036617/form4.xml","form_type":"4"}},{"id":1437424,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-08-09T20:05:22.000Z","date":"2024-08-07","kind":"grant","planned":true,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"These options, representing the right to purchase 5,000 shares, became exercisable in three installments, contingent upon continued service to the Company, with the first vesting date on March 20, 2015, which was the date on which the option was granted, and the final vesting date on May 1, 2015."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"These options, which were awarded on March 20, 2015, would otherwise expire and become forfeitable on March 20, 2025."}],"balance_after":0,"derivative":{"exercise_price":3.74,"underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0001140361-24-036617","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124036617/form4.xml","form_type":"4"}},{"id":1437423,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-09T20:05:22.000Z","date":"2024-08-07","kind":"sale","planned":true,"acquired":false,"shares":2000,"price":45.99,"value":91980.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":11900,"source":{"system":"sec-edgar","filing":"0001140361-24-036617","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124036617/form4.xml","form_type":"4"}},{"id":1437422,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-09T20:05:22.000Z","date":"2024-08-07","kind":"exercise","planned":true,"acquired":true,"shares":2000,"price":3.74,"value":7480.0,"ownership":{"direct":true},"balance_after":13900,"source":{"system":"sec-edgar","filing":"0001140361-24-036617","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124036617/form4.xml","form_type":"4"}},{"id":1437421,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-09T20:05:22.000Z","date":"2024-08-07","kind":"sale","planned":true,"acquired":false,"shares":5000,"price":45.92,"value":229600.0,"ownership":{"direct":true},"footnotes":[{"field":"acquired","element":"transactionAcquiredDisposedCode","label":"F1","text":"The sales reported in this Form 4 were effected by an automatic sale pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 11, 2024."}],"balance_after":11900,"source":{"system":"sec-edgar","filing":"0001140361-24-036617","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124036617/form4.xml","form_type":"4"}},{"id":1437420,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-08-09T20:05:22.000Z","date":"2024-08-07","kind":"exercise","planned":true,"acquired":true,"shares":5000,"price":3.74,"value":18700.0,"ownership":{"direct":true},"balance_after":16900,"source":{"system":"sec-edgar","filing":"0001140361-24-036617","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124036617/form4.xml","form_type":"4"}},{"id":1503414,"issuer":{"id":721,"kind":"organization","name":"Invivyd, Inc.","symbol":"IVVD"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-23T22:26:43.000Z","date":"2024-05-21","kind":"grant","planned":false,"acquired":true,"shares":100000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option was granted on May 21, 2024 and vests over a three-year period, with one-third of the shares subject to the grant vesting on the first anniversary of the grant date and 1/36th of the total shares subject to the grant vesting in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service through each vesting date."}],"balance_after":100000,"derivative":{"exercise_price":2.21,"expiration_date":"2034-05-20","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0000950170-24-064138","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000095017024064138/ownership.xml","form_type":"4"}},{"id":1529316,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2024-05-03T20:06:04.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs vest 100% on the earlier of May 1, 2025, or the date of the first Annual Meeting of Stockholders following May 1, 2024."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":3200,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-24-024330","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124024330/form4.xml","form_type":"4"}},{"id":1529315,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (Right to Buy)","published_at":"2024-05-03T20:06:04.000Z","date":"2024-05-01","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company."}],"balance_after":8000,"derivative":{"exercise_price":47.08,"expiration_date":"2034-05-01","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001140361-24-024330","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124024330/form4.xml","form_type":"4"}},{"id":1529314,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2024-05-03T20:06:04.000Z","date":"2024-05-01","kind":"exercise","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of May 3, 2024, or the date of the first Annual Meeting of Stockholders following May 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-24-024330","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124024330/form4.xml","form_type":"4"}},{"id":1529313,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2024-05-03T20:06:04.000Z","date":"2024-05-01","kind":"exercise","planned":false,"acquired":true,"shares":3200,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on May 3, 2023."}],"balance_after":11900,"source":{"system":"sec-edgar","filing":"0001140361-24-024330","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036124024330/form4.xml","form_type":"4"}},{"id":1773847,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-25T20:28:12.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a \"Tranche 2 Option\") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was equal to or greater than the amount of the Cash Consideration and less than the sum of the amount of the Cash Consideration and the amount of the DB-OTO Milestone Payment (as defined in the CVR Agreement) (each a \"Tranche 2 Option\") was cancelled and exchanged for one CVR with respect to each share subject to such Tranche 2 Option as of immediately prior to the Effective Time; provided that in the case of any CVR received in respect of a Tranche 2 Option, the DB-OTO Milestone Payment is equal to the excess of $6.00 over the exercise price per share with respect to such Tranche 2 Option and the Registration Study Milestone Payment (as defined in the CVR Agreement) is equal to $1.50 per CVR."}],"balance_after":0,"derivative":{"exercise_price":4.78,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000899243-23-019494","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000089924323019494/doc4.xml","form_type":"4"}},{"id":1773846,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2023-09-25T20:28:12.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":20000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a \"Tranche 1 Option\"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"At the Effective Time, pursuant to the Merger Agreement, each outstanding option to purchase shares of common stock of the Issuer having an exercise price per share that was less than the amount of the Cash Consideration (each a \"Tranche 1 Option\"), was cancelled and exchanged for (A) an amount in cash equal to the product of (x) the total number of shares subject to such Tranche 1 Option immediately prior to the Effective Time multiplied by (y) the excess of the amount of the Cash Consideration over the applicable exercise price per share of such Tranche 1 Option, and (B) one CVR with respect to each share subject to such Tranche 1 Option as of immediately prior to the Effective Time."}],"balance_after":0,"derivative":{"exercise_price":2.88,"expiration_date":"2032-10-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-23-019494","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000089924323019494/doc4.xml","form_type":"4"}},{"id":1773845,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2023-09-25T20:28:12.000Z","date":"2023-09-25","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":5000,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. (\"Parent\") and Symphony Acquisition Sub, Inc. (\"Purchaser\"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the \"Cash Consideration\"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a \"CVR\"),"},{"field":"shares","element":"transactionShares","label":"F2","text":"(Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the \"CVR Agreement\"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a \"Company RSU\"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU."},{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 5,000 unvested Company RSUs."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Pursuant to the terms of that certain Agreement and Plan of Merger (the \"Merger Agreement\"), by and among the Issuer, Regeneron Pharmaceuticals, Inc. (\"Parent\") and Symphony Acquisition Sub, Inc. (\"Purchaser\"), dated as of August 8, 2023, the shares of common stock, par value $0.001 per share, of the Issuer that were tendered prior to the Expiration Date (as defined in the Merger Agreement) and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) were exchanged for (i) $4.00 per share, payable in cash at closing, without interest and subject to reduction for any applicable withholding of taxes (the \"Cash Consideration\"), plus (ii) one contractual, non-tradeable contingent value right per share (each, a \"CVR\"),"},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 1) which entitles the holder to potentially receive contingent payments of up to an aggregate of $3.50 per CVR, without interest and subject to reduction for any applicable withholding taxes, upon the achievement of certain specified milestones in accordance with the terms and subject to the conditions of a Contingent Value Rights Agreement (the \"CVR Agreement\"), dated as of September 25, 2023, by and among Parent, Purchaser, Computershare Inc., and Computershare Trust Company, N.A. In addition, at the effective time of the merger (the \"Effective Time\"), pursuant to the Merger Agreement, each outstanding restricted stock unit of the Issuer (each a \"Company RSU\"), whether or not vested, was cancelled and exchanged for the right to receive (i) a cash payment equal to (x) the total numbers of shares subject to such Company RSU multiplied by (y) the Cash Consideration and (ii) one CVR with respect to each share subject to such Company RSU."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0000899243-23-019494","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000089924323019494/doc4.xml","form_type":"4"}},{"id":1855666,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-06-14T20:37:59.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option was granted on June 13, 2023 for 5,000 shares.  The shares underlying the option are scheduled to vest in full on the one year anniversary of the date of grant of the option (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the option), subject to the reporting person's continued service."}],"balance_after":5000,"derivative":{"exercise_price":4.78,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":5000},"source":{"system":"sec-edgar","filing":"0000950170-23-027990","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000095017023027990/ownership.xml","form_type":"4"}},{"id":1855665,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-06-14T20:37:59.000Z","date":"2023-06-13","kind":"grant","planned":false,"acquired":true,"shares":5000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of shares of the Issuer's common stock issuable under 5,000 restricted stock units (\"RSUs\").  Each RSU represents the right to receive one share of the Issuer's common stock upon vesting.  The RSUs are scheduled to vest in full on the one year anniversary of the date of grant of the RSUs (or, if earlier, the date of the next annual meeting of stockholders following the date of grant of the RSUs), subject to the reporting person's continued service."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 5,000 unvested RSUs.  Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting."}],"balance_after":5000,"source":{"system":"sec-edgar","filing":"0000950170-23-027990","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000095017023027990/ownership.xml","form_type":"4"}},{"id":1903476,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2023-05-05T20:04:52.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":3200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of May 3, 2024 or the date of the first Annual Meeting of Stockholders following May 3, 2023."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":3200,"derivative":{"underlying":"Common Stock","underlying_shares":3200},"source":{"system":"sec-edgar","filing":"0001140361-23-023198","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036123023198/form4.xml","form_type":"4"}},{"id":1903475,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Stock Option (right to buy)","published_at":"2023-05-05T20:04:52.000Z","date":"2023-05-03","kind":"grant","planned":false,"acquired":true,"shares":8000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company."}],"balance_after":8000,"derivative":{"exercise_price":32.12,"expiration_date":"2033-05-03","underlying":"Common Stock","underlying_shares":8000},"source":{"system":"sec-edgar","filing":"0001140361-23-023198","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036123023198/form4.xml","form_type":"4"}},{"id":1911711,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Restricted Stock Unit","published_at":"2023-04-28T20:04:41.000Z","date":"2023-04-27","kind":"exercise","planned":false,"acquired":false,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2600},"source":{"system":"sec-edgar","filing":"0001140361-23-021500","document":"form4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036123021500/form4.xml","form_type":"4"}},{"id":1911710,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true}}],"security":"Common Stock","published_at":"2023-04-28T20:04:41.000Z","date":"2023-04-27","kind":"exercise","planned":false,"acquired":true,"shares":2600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 27, 2022."}],"balance_after":8700,"source":{"system":"sec-edgar","filing":"0001140361-23-021500","document":"form4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000114036123021500/form4.xml","form_type":"4"}},{"id":2138172,"issuer":{"id":109458,"kind":"organization","name":"Decibel Therapeutics, Inc.","symbol":"DBTX"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-10-12T12:23:31.000Z","date":"2022-10-10","kind":"grant","acquired":true,"shares":20000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option was granted on October 10, 2022 for 20,000 shares. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service."}],"balance_after":20000,"derivative":{"exercise_price":2.88,"expiration_date":"2032-10-09","underlying":"Common Stock","underlying_shares":20000},"source":{"system":"sec-edgar","filing":"0000899243-22-033453","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1214938/000089924322033453/doc4.xml","form_type":"4"}},{"id":2288286,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-04-29T20:10:01.000Z","date":"2022-04-27","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs vest 100% on the earlier of April 27, 2023 or the date of the first Annual Meeting of Stockholders following April 27, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":2600,"derivative":{"underlying":"Common Stock","underlying_shares":2600},"source":{"system":"sec-edgar","filing":"0001593968-22-000890","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396822000890/primary_01.xml","form_type":"4"}},{"id":2288285,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2022-04-29T20:10:01.000Z","date":"2022-04-27","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company."}],"balance_after":6500,"derivative":{"exercise_price":31.99,"expiration_date":"2032-04-27","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001593968-22-000890","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396822000890/primary_01.xml","form_type":"4"}},{"id":2288284,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2022-04-29T20:10:01.000Z","date":"2022-04-27","kind":"exercise","acquired":false,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each RSU represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021. The first Annual Meeting of Stockholders occurred on April 27, 2022."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":2600},"source":{"system":"sec-edgar","filing":"0001593968-22-000890","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396822000890/primary_01.xml","form_type":"4"}},{"id":2288283,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2022-04-29T20:10:01.000Z","date":"2022-04-27","kind":"exercise","acquired":true,"shares":2600,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units (RSUs) granted to the Reporting Person on April 28, 2021."}],"balance_after":6100,"source":{"system":"sec-edgar","filing":"0001593968-22-000890","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396822000890/primary_01.xml","form_type":"4"}},{"id":2500481,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:03:19.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":18806,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":115.53,"underlying":"Common Stock","underlying_shares":18806},"source":{"system":"sec-edgar","filing":"0001104659-21-142266","document":"tm2133601-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142266/tm2133601-2_4seq1.xml","form_type":"4"}},{"id":2500480,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:03:19.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":24334,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":52.99,"underlying":"Common Stock","underlying_shares":24334},"source":{"system":"sec-edgar","filing":"0001104659-21-142266","document":"tm2133601-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142266/tm2133601-2_4seq1.xml","form_type":"4"}},{"id":2500479,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:03:19.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":20500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":41.64,"underlying":"Common Stock","underlying_shares":20500},"source":{"system":"sec-edgar","filing":"0001104659-21-142266","document":"tm2133601-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142266/tm2133601-2_4seq1.xml","form_type":"4"}},{"id":2500478,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:03:19.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":11262,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":40.61,"underlying":"Common Stock","underlying_shares":11262},"source":{"system":"sec-edgar","filing":"0001104659-21-142266","document":"tm2133601-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142266/tm2133601-2_4seq1.xml","form_type":"4"}},{"id":2500477,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-11-22T09:03:19.000Z","date":"2021-11-19","kind":"disposition_to_issuer","acquired":false,"shares":2663,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F2","text":"Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a \"Company Stock Option\") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of the Offer Price over the applicable exercise price per Share under such Company Stock Option."}],"balance_after":0,"derivative":{"exercise_price":30.17,"underlying":"Common Stock","underlying_shares":2663},"source":{"system":"sec-edgar","filing":"0001104659-21-142266","document":"tm2133601-2_4seq1.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142266/tm2133601-2_4seq1.xml","form_type":"4"}},{"id":2500476,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-11-22T09:03:19.000Z","date":"2021-11-19","kind":"other","acquired":false,"shares":10681,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"shares","element":"transactionShares","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the \"Merger Agreement\"), dated as of September 29, 2021, by and among the Issuer, Merck Sharp & Dohme Corp. (\"Parent\"), and Astros Merger Sub, Inc., a direct wholly owned subsidiary of Parent (\"Merger Sub\"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a \"Share\") and thereafter merged with and into the Issuer (the \"Merger\") effective as of November 19, 2021 (the \"Effective Time\"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $180.00 in cash (the \"Offer Price\") without interest and subject to applicable withholding taxes."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001104659-21-142266","document":"tm2133601-2_4seq1.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000110465921142266/tm2133601-2_4seq1.xml","form_type":"4"}},{"id":2559765,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-24","kind":"exercise","acquired":false,"shares":170,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019."}],"balance_after":20500,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":170},"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":13,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559764,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-24","kind":"exercise","acquired":false,"shares":5200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018."}],"balance_after":11262,"derivative":{"exercise_price":40.61,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":5200},"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559763,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":7330,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2019."}],"balance_after":20670,"derivative":{"exercise_price":41.64,"expiration_date":"2029-01-25","underlying":"Common Stock","underlying_shares":7330},"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559762,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":9800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2018."}],"balance_after":16462,"derivative":{"exercise_price":40.61,"expiration_date":"2028-03-01","underlying":"Common Stock","underlying_shares":9800},"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559761,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"exercise","acquired":false,"shares":2500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares of common stock underlying this stock option award vested in equal quarterly installments over the four years after January 1, 2017."}],"balance_after":2663,"derivative":{"exercise_price":30.17,"expiration_date":"2027-03-02","underlying":"Common Stock","underlying_shares":2500},"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559760,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-24","kind":"sale","acquired":false,"shares":5370,"price":160.38,"value":861240.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.08 to $160.70 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":10681,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559759,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-24","kind":"exercise","acquired":true,"shares":170,"price":41.64,"value":7078.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":16051,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559758,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-24","kind":"exercise","acquired":true,"shares":5200,"price":40.61,"value":211172.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":15881,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559757,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":983,"price":161.26,"value":158518.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $161.10 to $161.35 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":10681,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559756,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"sale","acquired":false,"shares":18647,"price":160.26,"value":2988368.22,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $160.00 to $160.89 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4."}],"balance_after":11664,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559755,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":7330,"price":41.64,"value":305221.2,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":30311,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559754,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":9800,"price":40.61,"value":397978.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":22981,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2559753,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-09-24T19:36:42.000Z","date":"2021-09-23","kind":"exercise","acquired":true,"shares":2500,"price":30.17,"value":75425.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":13181,"source":{"system":"sec-edgar","filing":"0001179110-21-008935","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021008935/edgar.xml","form_type":"4"}},{"id":2735062,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-04-30T20:09:15.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":2600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"These RSUs vest 100% on the earlier of April 28, 2022 or the date of the first Annual Meeting of Stockholders following April 28, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":2600,"derivative":{"underlying":"Common Stock","underlying_shares":2600},"source":{"system":"sec-edgar","filing":"0001593968-21-001210","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396821001210/primary_01.xml","form_type":"4"}},{"id":2735061,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Stock Option (right to buy)","published_at":"2021-04-30T20:09:15.000Z","date":"2021-04-28","kind":"grant","acquired":true,"shares":6500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option vests over a 1-year period, in equal monthly increments, contingent upon continued service to the Company."}],"balance_after":6500,"derivative":{"exercise_price":63.22,"expiration_date":"2031-04-28","underlying":"Common Stock","underlying_shares":6500},"source":{"system":"sec-edgar","filing":"0001593968-21-001210","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396821001210/primary_01.xml","form_type":"4"}},{"id":2735060,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Restricted Stock Unit","published_at":"2021-04-30T20:09:15.000Z","date":"2021-04-28","kind":"exercise","acquired":false,"shares":1750,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each Restricted Stock Unit (RSU) represents a contingent right to receive one share of common stock of Vericel Corporation."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"These RSUs vest 100% on the earlier of April 29, 2021 or the date of the first Annual Meeting of Stockholders following April 29, 2020. The first Annual Meeting of Stockholders occurred on April 28, 2021."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"No expiration date for this type of award."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":1750},"source":{"system":"sec-edgar","filing":"0001593968-21-001210","document":"primary_01.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396821001210/primary_01.xml","form_type":"4"}},{"id":2735059,"issuer":{"id":4481,"kind":"organization","name":"Vericel Corp"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Common Stock","published_at":"2021-04-30T20:09:15.000Z","date":"2021-04-28","kind":"exercise","acquired":true,"shares":1750,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The shares of common stock were acquired by the Reporting Person as a result of the vesting of Restricted Stock Units granted to the Reporting Person on April 29, 2020."}],"balance_after":3500,"source":{"system":"sec-edgar","filing":"0001593968-21-001210","document":"primary_01.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/887359/000159396821001210/primary_01.xml","form_type":"4"}},{"id":2885164,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Option to Purchase Common Stock","published_at":"2021-02-02T19:46:21.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":18806,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares of common stock underlying this stock option award vest in equal quarterly installments over the four years after January 1, 2021."}],"balance_after":18806,"derivative":{"exercise_price":115.53,"expiration_date":"2031-01-29","underlying":"Common Stock","underlying_shares":18806},"source":{"system":"sec-edgar","filing":"0001179110-21-001120","document":"edgar.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001120/edgar.xml","form_type":"4"}},{"id":2885163,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-02-02T19:46:21.000Z","date":"2021-01-29","kind":"grant","acquired":true,"shares":4868,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":10681,"source":{"system":"sec-edgar","filing":"0001179110-21-001120","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021001120/edgar.xml","form_type":"4"}},{"id":2915136,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":4,"price":123.5,"value":494.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."}],"balance_after":5813,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915135,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":296,"price":122.85,"value":36363.6,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F10","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.50 to $123.36 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (10) to this Form 4."}],"balance_after":5817,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915134,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":499,"price":121.89,"value":60823.11,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F9","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $121.26 to $122.25 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (9) to this Form 4."}],"balance_after":6113,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915133,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":700,"price":120.43,"value":84301.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $120.00 to $120.98 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (8) to this Form 4."}],"balance_after":6612,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915132,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":300,"price":124.45,"value":37335.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.31 to $125.65 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (7) to this Form 4."}],"balance_after":7312,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915131,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":667,"price":124.47,"value":83021.49,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.15 to $124.96 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (6) to this Form 4."}],"balance_after":7612,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915130,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":600,"price":123.49,"value":74094.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.08 to $123.93 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (5) to this Form 4."}],"balance_after":8279,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915129,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":200,"price":125.49,"value":25098.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $125.40 to $125.57 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (4) to this Form 4."}],"balance_after":8879,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}},{"id":2915128,"issuer":{"id":15780,"kind":"organization","name":"ACCELERON PHARMA INC","symbol":"XLRN"},"owners":[{"id":23536,"kind":"person","name":"MCLAUGHLIN KEVIN F","position":1,"cik":"0001214938","reported_name":"MCLAUGHLIN KEVIN F","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"SVP, CFO and Treasurer"}}],"security":"Common Stock","published_at":"2021-01-06T19:03:06.000Z","date":"2021-01-04","kind":"sale","acquired":false,"shares":713,"price":124.28,"value":88611.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported sales were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.13 to $124.62 inclusive. The reporting person undertakes to provide Acceleron Pharma Inc., any security holder of Acceleron Pharma Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (3) to this Form 4."}],"balance_after":9079,"source":{"system":"sec-edgar","filing":"0001179110-21-000365","document":"edgar.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1280600/000117911021000365/edgar.xml","form_type":"4"}}],"next_cursor":"2021-01-06T19:03:06.000000Z,2915128"}